TY - JOUR
T1 - Kit Gene in Endometrial Carcinoma An Immunohistochemical and Mutational Analysis
AU - Vandenput, Ingrid
AU - Debiec-Rychter, Maria
AU - Capoen, An
AU - Verbist, Godelieve
AU - Vergote, Ignace
AU - Moerman, Philippe
AU - Amant, Frédéric
PY - 2011
Y1 - 2011
N2 - Objective: Because the outcome of recurrent disease of endometrial carcinoma is cumbersome, the development of target treatment strategies is critical. We evaluated KIT, a receptor tyrosine kinase, to determine a potential role for imatinib mesylate in the treatment of endometrial carcinoma. Materials and Methods: Immunohistochemical analysis for KIT expression was performed on paraffin sections from 45 patients: 30 primary and 15 recurrent tumors. Fifteen primary cases were available for mutation analysis. Results: Histopathological distribution of paraffin-embedded tissue was as follows: 30 type I and 15 type II endometrial carcinoma. Histopathological distribution of fresh-frozen tissue was as follows: 8 type I and 7 type II. Cases did not show KIT expression or mutations in mutational hotspot exons of KIT gene. Conclusions: On the basis of the absence of KIT expression or mutations, endometrial carcinoma is unlikely to respond to imatinib mesylate
AB - Objective: Because the outcome of recurrent disease of endometrial carcinoma is cumbersome, the development of target treatment strategies is critical. We evaluated KIT, a receptor tyrosine kinase, to determine a potential role for imatinib mesylate in the treatment of endometrial carcinoma. Materials and Methods: Immunohistochemical analysis for KIT expression was performed on paraffin sections from 45 patients: 30 primary and 15 recurrent tumors. Fifteen primary cases were available for mutation analysis. Results: Histopathological distribution of paraffin-embedded tissue was as follows: 30 type I and 15 type II endometrial carcinoma. Histopathological distribution of fresh-frozen tissue was as follows: 8 type I and 7 type II. Cases did not show KIT expression or mutations in mutational hotspot exons of KIT gene. Conclusions: On the basis of the absence of KIT expression or mutations, endometrial carcinoma is unlikely to respond to imatinib mesylate
U2 - https://doi.org/10.1097/IGC.0b013e3182055c94
DO - https://doi.org/10.1097/IGC.0b013e3182055c94
M3 - Article
C2 - 21270602
SN - 1048-891X
VL - 21
SP - 203
EP - 205
JO - International journal of gynecological cancer
JF - International journal of gynecological cancer
IS - 2
ER -